hotspot -WSS

hotspot

author：fashion 2025-10-02 00:42:04 - browse：96

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： How Vertex's cystic fibrosis drug is changing patients' lives

entertainment

WSS

Medical student insurance fails on mental health care coverage

Ukraine and a new approach to mental health in war

STAT Summit: GSK CEO on pharma giant's new direction

Readout LOUD podcast: possible new ALS drug, artificial wombs

Will Ozempic

Will Ozempic

explore

hotspot

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: GSK CEO on pharma giant's new direction

Walensky prepares to leave CDC — and Congress — behind

STAT Virtual Event: Putting AI to the Test

United colonoscopy coverage change 'may cost lives,' doctors say

Changes to biosimilar regulatory framework must prioritize patients

ChatGPT in medicine: STAT answers readers' burning questions

Why are Kaiser Permanente staff considering a strike?

Medical records are filled with copy

Lasker Awards 2023: Winners in biomedical research

entertainment

It's been 20 years since Dolly the sheep. Where's my clone?

Microbiome research is starting to find links to chronic diseases

STAT Virtual Event: Putting AI to the Test

Biotech stock slump in 2023: awaiting the turnaround

Senators: Long

CommonSpirit Health keeps growing, even as it loses money

hotspot

entertainment

entertainment

hotspot